| Name | Title | Contact Details |
|---|
Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero`s existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.
We are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets.
Pharmathen is a Hammond, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Verseon is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kira Pharmaceuticals is pioneering complement drug discovery to deliver transformative therapies for people with complement-mediated diseases